Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Crossref DOI link: https://doi.org/10.1007/s41669-022-00372-0
Published Online: 2022-09-15
Published Print: 2022-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Elsea, David
Fan, Lin
Mihai, Adela
Moustaid, Fadoua El
Simmons, Daniel
Monberg, Matthew
Muston, Dominic
Text and Data Mining valid from 2022-09-15
Version of Record valid from 2022-09-15
Article History
First Online: 15 September 2022